JAMA/tukuz.com
Feb 7, 2026, 06:50
ACOG 2023 Guideline on Premenstrual Disorders – JAMA
JAMA shared a post on LinkedIn:
“JAMA Clinical Guidelines Synopsis: The 2023 American College of Obstetricians and Gynecologists guideline on the management of premenstrual disorders recommends selective serotonin reuptake inhibitors (SSRIs)—used intermittently or continuously—as effective for affective symptoms, with evidence supporting their use.
Combined oral contraceptive pills, particularly those containing drospirenone, and cognitive behavior therapy are also recommended.
Treatment selection should consider individual patient goals, presence of affective or physical symptoms, and need for contraception.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
May 29, 2026, 19:40The Great Egg Escape: Understanding Premature Ovulation in IVF – Fertility Plus
-
May 29, 2026, 19:38Devyanshi Dixit: Call for Abstract for GFWH 2026
-
May 29, 2026, 19:35Tom Holland: Advancing Robotic Surgery Skills at the T400 Course in Strasbourg
-
May 29, 2026, 19:33Silpi Saikia: Not Every Successful Blastocyst Comes From an Easy Case!
-
May 29, 2026, 19:31Register Now and Secure Your Spot at ASRM 2026 – ASRM
-
May 29, 2026, 19:29Sonam Jain: The Real Driver of IVF Conversion Is Patient Trust
-
May 29, 2026, 19:26Mediterranean Diet Before IVF Increases Successful Pregnancies by 40%! – Fertility Plus
-
May 29, 2026, 19:24Melanie Norton: Excited to Begin My Robotics Fellowship at UCLH
-
May 29, 2026, 19:22A Step Forward in Non-Invasive Diagnosis of Endometriosis – The Lancet Medical Imaging and Theranostics